The Top 5 Biosimilar Articles for the Week of November 20

Number 5: The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.

Number 4: In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars^® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.

Number 3: At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Number 2: In part 1 of a 3-part series for Global Biosimilars Week The Center for Biosimilars looks at a retrospective study comparing the clinical benefits, price changes, and uptake associated with oncology biosimilars in China.

Number 1: In part 3 of a 3-part series for Global Biosimilars Week The Center for Biosimilars reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.

To read all of these articles and more, visit centerforbiosimilars.com.